A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder

被引：0
|
作者：
Phiri, Kelesitse [1 ]
Hallas, Jesper [2 ]
Linder, Marie [3 ]
Margulis, Andrea [4 ]
Suehs, Brandon [5 ]
Arana, Alejandro [4 ]
Bahmanyar, Shahram [3 ]
Enger, Cheryl [1 ]
Horter, Libby [5 ]
Odsbu, Ingvild [3 ]
Olesen, Morten [2 ]
Perez-Gutthann, Susana [4 ]
Kristiansen, Nina Sahlertz [2 ]
Appenteng, Kwame [6 ]
de Vogel, Stefan [7 ]
Seeger, John [1 ]
机构：
[1] Optum, Boston, MA USA
[2] Univ Southern Denmark, Odense, Denmark
[3] Karolinska Inst, Stockholm, Sweden
[4] RTI Hlth Solut, Barcelona, Spain
[5] Humana Healthcare Res, Louisville, KY USA
[6] Astellas Pharma US, Northbrook, IL USA
[7] Astellas Pharma BV, Leiden, Netherlands
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2020年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
4352
引用
收藏
页码：465 / 465
页数：1
相关论文
共 50 条
  • [11] Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia
    Parise, Helene
    Espinosa, Robert
    Dea, Katherine
    Anaya, Pablo
    Montoya, Giovanny
    Bin Ng, Daniel
    PHARMACOECONOMICS-OPEN, 2020, 4 (01) : 79 - 90
  • [12] Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia
    Hélène Parise
    Robert Espinosa
    Katherine Dea
    Pablo Anaya
    Giovanny Montoya
    Daniel Bin Ng
    PharmacoEconomics - Open, 2020, 4 : 79 - 90
  • [13] COST-UTILITY ANALYSIS OF MIRABEGRON VERSUS ANTIMUSCARINIC THERAPY IN THE TREATMENT OF OVERACTIVE BLADDER
    Majd, Karimi Z.
    Taheri, S.
    Yousefi, N.
    Peiravian, F.
    VALUE IN HEALTH, 2019, 22 : S915 - S916
  • [14] Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population
    Johnson, Theodore M., II
    Walker, David
    Lockefeer, Amy
    Jiang, Baoguo
    Nimke, David
    Lozano-Ortega, Greta
    Kimura, Tomomi
    NEUROUROLOGY AND URODYNAMICS, 2022, 41 (08) : 1872 - 1889
  • [15] Pregnancy among Users of Antimuscarinic Drugs Indicated for the Treatment of Overactive Bladder
    Kremer, Barbara K.
    Quan, Shung-Ping
    Patadia, Vaishali
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 : S53 - S53
  • [16] Mirabegron, a novel, non-antimuscarinic drug for the overactive bladder: An up-to-dated review
    Emilio Sacco
    Riccardo Bientinesi
    World Journal of Obstetrics and Gynecology, 2013, (04) : 65 - 73
  • [17] Cost analysis of overactive bladder treatments for oral antimuscarinic refractory patients
    Watanabe, Jonathan H.
    Campbell, Jonathan D.
    Ravelo, Arliene
    Chancellor, Michael B.
    Kowalski, Jonathan W.
    Sullivan, Sean D.
    JOURNAL OF UROLOGY, 2008, 179 (04): : 55 - 56
  • [18] MIRABEGRON FOR THE TREATMENT OF OVERACTIVE BLADDER
    Gras, J.
    DRUGS OF TODAY, 2012, 48 (01) : 25 - 32
  • [19] Mirabegron approved for overactive bladder
    Traynor, Kate
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2012, 69 (15) : 1270 - 1270
  • [20] Mirabegron in the treatment of overactive bladder
    Maggiore, Umberto Leone Roberti
    Cardozo, Linda
    Ferrero, Simone
    Sileo, Filomena
    Cola, Alice
    Torella, Marco
    Colacurci, Nicola
    Candiani, Massimo
    Salvatore, Stefano
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (06) : 873 - 887
12345